$EVOK
Evoke Pharma Inc

2019 Q4 Form 10-K Financial Statement

#000156459020010254 Filed on March 12, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $780.0K $810.0K $1.220M
YoY Change -27.1% -10.0% 18.45%
% of Gross Profit
Research & Development $641.5K $822.4K $746.9K
YoY Change -8.35% 30.55% -46.09%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $641.5K $1.637M $746.9K
YoY Change -63.75% 7.68% -69.11%
Operating Profit -$1.637M
YoY Change 7.49%
Interest Expense $10.00K $8.597K $0.00
YoY Change 0.0% 178.31% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $8.597K $0.00
YoY Change 178.31% -100.0%
Pretax Income -$1.420M -$1.630M -$1.970M
YoY Change -19.32% 7.24% -0.51%
Income Tax
% Of Pretax Income
Net Earnings -$1.418M -$1.628M -$1.965M
YoY Change -19.45% 7.15% -0.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$58.41K -$67.55K -$112.7K
COMMON SHARES
Basic Shares Outstanding 24.23M 17.43M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.660M $6.500M $4.030M
YoY Change 6.39% -1.07% -25.51%
Cash & Equivalents $5.664M $6.505M $4.029M
Short-Term Investments
Other Short-Term Assets $11.55K $11.55K
YoY Change -97.37% -93.58%
Inventory
Prepaid Expenses $581.7K $775.6K
Receivables
Other Receivables
Total Short-Term Assets $6.246M $7.292M $4.260M
YoY Change 10.58% 4.02% -23.66%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $40.00K $100.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.55K $0.00 $0.00
YoY Change 0.0% -100.0%
Total Long-Term Assets $150.1K $35.40K $100.0K
YoY Change 1199.36% 253.98%
TOTAL ASSETS
Total Short-Term Assets $6.246M $7.292M $4.260M
Total Long-Term Assets $150.1K $35.40K $100.0K
Total Assets $6.396M $7.327M $4.360M
YoY Change 13.0% 4.38% -21.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.030M $1.150M $490.0K
YoY Change 114.58% 82.54% -10.91%
Accrued Expenses $980.0K $1.000M $800.0K
YoY Change -15.52% 2.04% 23.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.015M $2.154M $1.290M
YoY Change 23.29% 33.8% 7.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.015M $2.154M $1.290M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.015M $2.150M $1.290M
YoY Change 23.62% 33.54% 7.9%
SHAREHOLDERS EQUITY
Retained Earnings -$85.73M -$84.31M
YoY Change 9.07%
Common Stock $90.11M $89.49M
YoY Change 9.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.381M $5.173M $3.075M
YoY Change
Total Liabilities & Shareholders Equity $6.396M $7.327M $4.360M
YoY Change 13.0% 4.38% -21.93%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q1
OPERATING ACTIVITIES
Net Income -$1.418M -$1.628M -$1.965M
YoY Change -19.45% 7.15% -0.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.150M -$1.050M -$1.927M
YoY Change -8.0% -8.7% -31.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $636.4K
YoY Change 16.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 120.0K 636.4K
YoY Change -89.92% 16.85%
NET CHANGE
Cash From Operating Activities -1.150M -1.050M -1.927M
Cash From Investing Activities
Cash From Financing Activities 310.0K 120.0K 636.4K
Net Change In Cash -840.0K -930.0K -1.290M
YoY Change -32.8% -2425.0% -43.23%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$1.050M -$1.927M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Assets Current
AssetsCurrent
5648222
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2019 dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8014685
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28798
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24431914
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17427533
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24431914
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17427533
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019 dei Trading Symbol
TradingSymbol
EVOK
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 dei Entity File Number
EntityFileNumber
001-36075
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2019 dei City Area Code
CityAreaCode
858
CY2019 dei Local Phone Number
LocalPhoneNumber
345-1494
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5663833
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
581706
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
329218
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6245539
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138538
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1743
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82628312
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78604735
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5659773
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3416466
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4095014
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3737987
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3919671
CY2019 us-gaap Operating Expenses
OperatingExpenses
7154453
CY2018 us-gaap Operating Expenses
OperatingExpenses
8014685
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
448605
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-7125655
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-7566080
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
47057
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4571240
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6106922
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1539469
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3267885
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1373958
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6978560
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4618297
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4618297
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
344829
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2360263
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7679267
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company relies on contract research organizations (&#8220;CROs&#8221;) and consultants to assist with ongoing regulatory discussions and submissions supporting the NDA. If the CROs and consultants are unable to continue their support, this could adversely affect FDA&#8217;s review of the NDA.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, if approved by FDA, and the development and/or commercialization of Gimoti could be materially and adversely affected. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on third-party sales and marketing organizations for the management of the pre-commercial launch preparation for Gimoti, as well as for a dedicated sales team to sell Gimoti, if approved by FDA.&nbsp;&nbsp;If such third-party organizations are unable to continue managing the launch preparation, or serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.</p>
CY2018Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2028-02
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.75
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
2456999
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1842746
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2019 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2019Q4 evok Shares Of Common Stock Subject To Registration Rights
SharesOfCommonStockSubjectToRegistrationRights
1509789
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2713561
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2713561
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.91
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.91
CY2018 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y14D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.62
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
1.62
CY2018 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
2.48
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.91
CY2019 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2019Q2 evok Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
1.00
CY2019Q2 evok Initial Period To Regain Compliance
InitialPeriodToRegainCompliance
P180D
CY2019 evok Closing Bid Price Description
ClosingBidPriceDescription
On May 15, 2019, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market. In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until November 11, 2019, to regain compliance. The Nasdaq letter had no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on the Nasdaq Capital Market.
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
18791
CY2019 evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-12-31
CY2019 evok Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.12
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
136000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
136000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
145000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
139000
CY2019Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
146000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2019 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y14D
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6286425
CY2018Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
47000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
CY2019Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
263065
CY2018 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
420000
CY2019Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
746882
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
28869
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1205599
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
822444
CY2019Q4 evok Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
39000
CY2019Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
237000
CY2018Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
244000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1202000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
899000
CY2019Q4 evok Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
39000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
39000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1163000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
899000
CY2019 evok Percentage Of Taxable Income Offset By Tax Losses
PercentageOfTaxableIncomeOffsetByTaxLosses
0.80
CY2019 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2018 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2100000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M26D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3114371
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3017624
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1587155
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
986801
CY2018Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
163065
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7678152
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6881051
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.04
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2018 evok Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant Liability Adjustment
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrantLiabilityAdjustment
0.01
CY2019 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.03
CY2018 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.04
CY2019 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.27
CY2018 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.22
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.04
CY2019 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.04
CY2018 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.03
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19000000
CY2019 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2019 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3500000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
80000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
81000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
846000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
574000
CY2019Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
641541
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23258567
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1223013
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918139
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
814218
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
782617
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965266
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2114096
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1628065
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-1418228
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17484318
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24128060
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24313411
CY2018Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1385366
CY2018Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1388791
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1032245
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
917305
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1982786
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15427037

Files In Submission

Name View Source Status
0001564590-20-010254-index-headers.html Edgar Link pending
0001564590-20-010254-index.html Edgar Link pending
0001564590-20-010254.txt Edgar Link pending
0001564590-20-010254-xbrl.zip Edgar Link pending
evok-10k_20191231.htm Edgar Link pending
evok-20191231.xml Edgar Link completed
evok-20191231.xsd Edgar Link pending
evok-20191231_cal.xml Edgar Link unprocessable
evok-20191231_def.xml Edgar Link unprocessable
evok-20191231_lab.xml Edgar Link unprocessable
evok-20191231_pre.xml Edgar Link unprocessable
evok-ex1026_373.htm Edgar Link pending
evok-ex231_6.htm Edgar Link pending
evok-ex311_11.htm Edgar Link pending
evok-ex312_8.htm Edgar Link pending
evok-ex321_10.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
evok-ex49_632.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gzai4iaakxvy000001.jpg Edgar Link pending
gzai4iaakxvy000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending